David Kim
@Paradigm Biocapital Advisors Lp
Latest period2024 - Q3ReportedManaged Assets$2.956BTotal holdings31
Assets growth rate13.13%Assets growth rate (2-Q avg)2.56%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Paradigm Biocapital Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 31 positions.
Assets under management
The assets under management (AUM) of Paradigm Biocapital Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.956B in assets, with a quarterly growth rate of 13.13% and a 2-quarter average growth rate of 2.56%. The portfolio is managed by David Kim, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
NUVLNuvalent Inc
| 17.31% | $511.5M 5M shares@ $102.3 avg price | Increased 9.37% |
ACLXArcellx Inc
| 13.57% | $400.848M↑ Call 4.8M shares@ $83.51 avg price | Increased 24.74% |
ARGXArgenx Se
| 8.81% | $260.401M 480,374 shares@ $542.09 avg price | Decreased -10.73% |
RVMDRevolution Medicines Inc
| 8.16% | $240.994M 5.314M shares@ $45.35 avg price | Increased 1.05% |
CRNXCrinetics Pharmaceuticals In
| 4.36% | $128.603M 2.517M shares@ $51.11 avg price | Increased 0.14% |
MRUSMerus N V
| 4.15% | $122.648M 2.455M shares@ $49.96 avg price | Increased 21.55% |
JANXJanux Therapeutics Inc
| 3.69% | $109.058M 2.401M shares@ $45.44 avg price | Increased 53.45% |
PCVXVaxcyte Inc
| 3.5% | $103.361M↑ Call 904,532 shares@ $114.28 avg price | Increased 44.22% |
KURAKura Oncology Inc
| 2.87% | $84.634M 4.331M shares@ $19.54 avg price | Decreased -4.58% |
TARSTarsus Pharmaceuticals Inc
| 2.72% | $80.266M 2.44M shares@ $32.89 avg price | Increased 0.21% |